Vaccination of Melanoma Patients with Dendritic Cells
Author Information
Author(s): Erika M von Euw, María M Barrio, David Furman, Estrella M Levy, Michele Bianchini, Isabelle Peguillet, Olivier Lantz, Alejandro Vellice, Abraham Kohan, Matías Chacón, Cassian Yee, Rosa Wainstok, José Mordoh
Primary Institution: Centro de Investigaciones Oncológicas FUCA
Hypothesis
Can a vaccine composed of dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells induce an immune response in melanoma patients?
Conclusion
The DC/Apo-Nec vaccine is safe, well tolerated, and may induce specific immunity against melanoma antigens.
Supporting Evidence
- Patients with a low-producing IL-10 polymorphism appear to have a worse prognosis.
- The vaccine was well tolerated in all patients.
- DTH scores increased significantly after the first vaccination.
- Immature DCs efficiently phagocytosed melanoma Apo-Nec cells.
- 7/8 stage III patients remain disease-free after treatment.
Takeaway
This study tested a new vaccine for melanoma patients made from special immune cells that help the body fight cancer, and it seems to work well without causing serious side effects.
Methodology
Patients received four vaccinations of dendritic cells loaded with apoptotic/necrotic melanoma cells, and immune responses were measured using ELISpot and tetramer analysis.
Potential Biases
Potential bias due to the small number of patients and lack of a control group.
Limitations
The study had a small sample size and was limited to a Phase I trial, which restricts the ability to draw broad conclusions.
Participant Demographics
16 melanoma patients (5 females, 11 males) aged 17-60, with stages IIC, III, and IV melanoma.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website